Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The company employs 127 people and has generated $50 million in revenue. Praxis focuses on developing therapies for central nervous system disorders that involve imbalances in neuronal activity. Their approach involves utilizing genetic insights to identify biological targets for both rare and common neurological diseases. They aim to create high-impact medicines for patients and families dealing with complex brain disorders. Praxis employs two proprietary platforms in their drug discovery and development process: Cerebrum™, a small molecule platform, and Solidus™, an antisense oligonucleotide platform. Both platforms leverage their understanding of shared biological targets and circuits in the brain. For more information, visit praxismedicines.com.